Prothrombin and factor V polymorphisms in a Latin American cohort with heart failure and type 2 diabetes.

10 October 2023, Version 1
This content is an early or alternative research output and has not been peer-reviewed by Cambridge University Press at the time of posting.

Abstract

Introduction : The study of the role of genetic markers of hemostasis disorders in CHF with both preserved (HFPEF) and reduced (HFREF) LVEF in patients with DM2 has not been adequately addressed . Methods : We used “ Genetics of Hemostasis ” kits from the company DNA Technology (USA). Amplification was performed in a DT-Prime 5 amplifier (DNA Technology , USA) for the prothrombin and factor V gene polymorphisms. Results: F13 (rs5985) and fibrinogen (rs1800790): they are more common in patients with HFPEF and DM2 than in the control group and in patients with HFREF ; ITGA2 (rs1126643): was less common in the HFPEF group than in the control group; ITGB3 (rs5918) and PAI-1 (rs1799889) rs5918 are more common than in the control group and HFPEF group. Conclusions : We encourage carrying out this type of studies since they are scarce in the regional literature.

Keywords

Diabetes Mellitus
Polymorphism
Prothrombin
Heart Failure

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting and Discussion Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.